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Abstract
Ten outbreaks of poliomyelitis caused by pathogenic circulating vaccine-derived polioviruses (cVDPVs) have recently been
reported in different regions of the world. Two of these outbreaks occurred in Madagascar. Most cVDPVs were
recombinants of mutated poliovaccine strains and other unidentified enteroviruses of species C. We previously reported
that a type 2 cVDPV isolated during an outbreak in Madagascar was co-circulating with coxsackieviruses A17 (CA17) and
that sequences in the 39 half of the cVDPV and CA17 genomes were related. The goal of this study was to investigate
whether these CA17 isolates can act as recombination partners of poliovirus and subsequently to evaluate the major effects
of recombination events on the phenotype of the recombinants. We first cloned the infectious cDNA of a Madagascar CA17
isolate. We then generated recombinant constructs combining the genetic material of this CA17 isolate with that of the type
2 vaccine strain and that of the type 2 cVDPV. Our results showed that poliovirus/CA17 recombinants are viable. The
recombinant in which the 39 half of the vaccine strain genome had been replaced by that of the CA17 genome yielded
larger plaques and was less temperature sensitive than its parental strains. The virus in which the 39 portion of the cVDPV
genome was replaced by the 39 half of the CA17 genome was almost as neurovirulent as the cVDPV in transgenic mice
expressing the poliovirus cellular receptor gene. The co-circulation in children and genetic recombination of viruses,
differing in their pathogenicity for humans and in certain other biological properties such as receptor usage, can lead to the
generation of pathogenic recombinants, thus constituting an interesting model of viral evolution and emergence.
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Introduction
The Sabin’s trivalent live-attenuated oral poliovirus vaccine
(OPV) includes viral strains of three serotypes (Sabin 1, 2 and 3).
These strains replicate in the digest tract following vaccination,
inducing a strong local intestinal immune response that limits
subsequent poliovirus (PV) replication and viral transmission in
humans [1]. OPV is the main tool used in the Poliomyelitis
Eradication Initiative, which was launched by the World Health
Organization (WHO) in 1988 to eradicate this acute paralytic
disease (http://www.polioeradication.org/). Following intense
vaccination campaigns, wild polioviruses have disappeared from
major parts of the world, remaining endemic in only four
countries, India, Pakistan, Afghanistan and Nigeria [2]. Never-
theless, low vaccine coverage over recent years has allowed
occasional spread of wild PV strains from endemic countries to
neighboring or distant countries where wild PV had disappeared
[3]. Moreover, low vaccine coverage can lead to transmission of
OPV strains to non-immunized people, allowing genetic drift
and subsequent loss of their attenuation characteristics [4,5].
Ten outbreaks due to pathogenic circulating vaccine-derived
polioviruses (cVDPVs) have recently been reported, two of which
occurred in Madagascar in 2001–2002 and 2005 [3,6–13].
All but one of the cVDPV outbreaks were due to recombinant
lineages between vaccine PVs and other unidentified human
enteroviruses of species C (HEV-C) [3,6–13]. HEV-C (Picornavir-
idae family) include PVs and related coxsackie A virus serotypes
[14–16] (http://www.ictvonline.org/). Enteroviruses are non-
enveloped viruses with a single positive-strand RNA genome
approximately 7.5 kb long. The single large coding region of the
genome is flanked by 59 and 39-untranslated regions (59- and
39UTR). The coding region is translated as a single polyprotein,
which is then processed by viral proteases to yield mature viral
proteins including the capsid proteins (VP1 to VP4) and non-
structural proteins [17]. In recombinant cVDPV genomes, large
parts of the region encoding non-structural proteins, the 39UTR
and in some cases the 59UTR are derived from non-poliovaccine
HEV-C [5–7,9,10].
Recombination in enteroviruses was discovered in 1962 [18,19].
The ability of enteroviruses to undergo extensive recombination is
now well established, and represents another mechanism, together
with mutations, by which these viruses generate diversity and
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repair of deleterious mutations in genomes [4,30]. However, the
role of recombination in the generation and function of
recombinant strains — in particular of the newly discovered
recombinant cVDPVs — remains unclear [5,21,22].
During the polio-outbreak in 2001–2002 in Madagascar, two
different type 2 recombinant cVDPV lineages, with sequences
derived from the 59 half of the Sabin 2 genome and the 39 half of
non-PV HEV-C, were isolated. [11,27]. Recombination sites were
located in the region encoding viral protease 2A. Moreover, many
coxsackie A serotypes showing substantial genetic diversity were
found in the stools of children living in the small area where most
of the poliomyelitis cases occurred [27]. Partial genomic
sequencing showed that the sequences of several serotype 17 and
13 coxsackie A viruses (CA17 and CA13) encoding viral proteins
2C and 3D
pol (polymerase), respectively, were closely related to
those of the cVDPV sequences. These results suggest that
ancestors of these CA17 and CA13 strains were the donors of
the HEV-C sequences present in the Madagascar cVDPVs;
however, the nucleotide (nt) sequences showing the highest
similarity between these coxsackie A viruses and cVDPVs
remained significantly different (6–8%). Although these cVDPVs
and coxsackie A viruses appear to have common ancestors, the
observed differences in nt sequence could have been generated
either before or after the recombination event. Finally, other
coxsackie A viral strains or serotypes with sequences more closely-
related to those of the cVDPVs may have acted as parental
donors.
The infectious cDNA of one Madagascar cVDPV (MAD04)
belonging to the major lineage isolated in 2002 was cloned and
used with that of the original Sabin 2 vaccine strain to construct
cDNA-derived recombinants [31]. The results demonstrated that
the HEV-C sequences affected the characteristics of this cVDPV.
In particular, although the key neurovirulence determinants of
MAD04 are located in the 59 half of the genome (mutated Sabin 2
sequences), the HEV-C-derived 39 half of the genome affected
pathogenicity. However, it is not known whether this effect was
due to the primary recombination event involved in the generation
of the cVDPV or to subsequent mutations optimizing the
functional interactions between both halves of the genome.
We determined whether CA17 strains can be recombination
partners of PV and evaluated the key effects of such a
recombination event on the phenotype of the recombinants. We
cloned the infectious cDNA of a CA17 isolate and used it in
conjunction with that of Sabin 2 and MAD04 to construct and
characterize chimeric viruses. We found that non-polio HEV-C
sequences present in MAD04 can be replaced by CA17 sequences,
and that CA17 sequences contribute to the phenotypic character-
istics of PV/CA17 recombinants, including pathogenicity.
Results
Genomic sequencing and characterization of the
Madagascar CA17.67591 strain
To confirm the relationship between CA17 isolates and the
cVDPV MAD04 lineage, we sequenced the whole genome of one
of the CA17 isolates (CA17.67591) that was found co-circulating
with MAD04 [27] – EMBL Genbank accession number
FM955278. The genome of this isolate is 7457 nt long, excluding
the poly(A) tail. The CA17.67591 genome encodes a single open-
reading frame (encoding a 2213 amino-acid polyprotein) flanked
by a 747 nt 59UTR and a 71 nt 39UTR.
The nt sequences encoding the VP1 capsid protein of
enterovirus isolates are serotype-specific [32]. In an alignment of
VP1 nt sequences of CA17.67591 with those of HEV-C prototype
strains, the CA17-G12 prototype strain showed the highest nt
identity (78%). Alignment of the CA17.67591 VP1 polypeptide
also showed high sequence similarity with the VP1 polypeptide of
this prototype strain (94%). VP1-encoding genomic regions of
both CA17 strains were 918 nt long and differed from those of the
other prototype HEV-C strains. Given that enteroviruses of the
same serotype generally have .75% nt sequence identity and
.85% amino-acid similarity in VP1 regions, these results strongly
suggest that the CA17.67591 strain belongs to the same serotype
as the prototype strain CA17-G12 [32–34]. These results were
confirmed by aligning and comparing P1 genomic region
nucleotide sequences encoding the capsid proteins of
CA17.67591 and of various HEV-C prototypes in phylogenetic
trees (maximum likelihood method) (Fig. 1). P1 sequences from
CA17.67591 clustered with those of CA17-G12 with high
reliability values (percent puzzle steps $90%). Similar results
were obtained using VP1 nucleotide sequences (not shown). The
stem-loop structure containing the AAACA conserved motif,
constituting the cis-acting replication element cre(2C), was found in
CA17.67591 at nt positions 4461–4521 [35–37].
Several non-PV HEV-C (CA13, CA15, CA20 and CA21) bind
intercellular adhesion molecule-1 (ICAM-1), which thus acts as a
viral cellular receptor (or at least a co-receptor); in most cases, the
binding of these strains to cells can be blocked by anti-ICAM-1
antibodies [15,38,39]. The CA17 receptor is currently unknown.
We therefore tested whether CA17 infection was mediated by
ICAM-1, using the prototype CA17-G12 and the isolate
CA17.67591. Infection of HEp-2c cells by these two CA17 strains
was completely inhibited by the anti-ICAM-1 mAb 8.4 A6 [40],
but not by the anti-CD155 mAb 404 [41] directed against the PV
receptor (data not shown). Conversely, HEp-2c cells were
completely protected from Sabin 2 infection by the anti-CD155
mAb, but not by the anti-ICAM-1 mAb. These results suggested
that infection by CA17-G12 or CA17-67591 is mediated by
ICAM-1, as observed for the other non-PV HEV-C.
Author Summary
Following intense vaccination campaigns with Sabin’s
trivalent live-attenuated oral poliovirus vaccine, poliomy-
elitis caused by wild polioviruses has disappeared from
large parts of the world. However, poliomyelitis outbreaks
due to pathogenic circulating vaccine-derived polioviruses
(cVDPVs) have recently been reported in countries with
low vaccine coverage. Most of these cVDPVs seem to be
recombinants of mutated vaccine strains and undeter-
mined coxsackieviruses. We have previously shown a
cVDPV isolated during an outbreak in Madagascar to be
co-circulating with coxsackievirus A17 (CA17) strains with
39 genomic sequences related to those of the cVDPV. In
this study, we determined whether these CA17 isolates can
act as recombination partners of poliovirus. Using genetic
engineering techniques, we constructed a variety of
recombinant viruses derived from a CA17 isolate, the
cVDPV and the corresponding original vaccine strain. Our
results showed that poliovirus/CA17 recombinants are
viable. Moreover, the recombinant virus resulting from the
replacement of the 39 half of the cVDPV genome by that of
the CA17 genome was almost as pathogenic as the cVDPV.
This supports the notion that co-circulation and co-
evolution through the recombination of polioviruses and
coxsackieviruses contribute to the emergence of epidemic
cVDPVs. This constitutes an interesting model of viral
evolution and emergence.
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sequences from Madagascar
We carried out an overall comparative analysis of the genomic
nt sequences of the two Madagascar cVDPV lineages (MAD04
and MAD29), Sabin 2 and the prototype strains CA17-G12 and
CA13 Flores, by alignment with CA17.67591 nt sequences.
Pairwise comparisons were performed using similarity scanning
analysis [42] (Fig. 2A). The highest similarity score was obtained
for comparison of the 59 half of the CA17-G12 sequence (59UTR
and capsid region) with the homologous regions of CA17.67591,
confirming that these strains belong to the same HEV-C serotype.
High similarity scores were also observed when comparing the
MAD04 and MAD29 cVDPV nt sequences encoding viral
proteins 2B and 2C with those of CA17.67591, This was
confirmed by comparing in a more detailed analysis nucleotide
sequences — and to a lesser extent, amino-acid sequences — of
genomic regions of CA17.67591, with those of other HEV-C
(Table 1). Similar results were previously obtained from partial
sequencing of CA17.67591 [27], suggesting that ancestors of
CA17.67591 and other related CA17 isolates from Madagascar
were the donor strains of some of the non-poliovirus sequences
present in MAD04 and MAD29.
Recombination possibility between these three strains was
investigated with the bootscanning method [43] (Fig. 2B). These
results confirmed that the MAD04 sequences encoding proteins
2B and 2C and the MAD29 2C and 3AB sequences are closely
related to those of CA17.67591 and might have been acquired
from a recent ancestor of this strain. In contrast, genomic regions
encoding viral proteins 3C and 3D
pol (P3 region) and the 39UTR
of MAD04 and MAD29 did not show higher similarity with the
homologous regions of CA17.67591 than those of the prototype
HEV-C strains. These cVDPV sequences may originate from
other Madagascar HEV-C strains. From previous results based on
partial sequencing of the 3D
pol region, the cVDPV MAD04 and
certain CA13 strains appeared to have a relatively recent common
ancestor [27].
Molecular cloning of CA17.67591 infectious cDNA and
construction of chimeric viruses
To confirm that CA17.67591 could be a recombination partner
of PV and to determine main effects of this recombination event
on the phenotype of recombinants, we cloned the infectious cDNA
of this strain. Although the original isolate differs from the cDNA
by a few nucleotides (mentioned in the chapter Materials and
Methods), the cDNA-derived virus exhibited phenotypic charac-
teristics similar to those of the original isolate as indicated below.
We then used the cloned cDNA together with those of Sabin 2 and
MAD04 to construct chimeric viruses (Fig. 3). The recombination
site used for these constructs (nt position 3827, according to Sabin
2 nt numbering) was close to the natural site of recombination
between mutated Sabin 2 and non-poliovirus sequences (nt 3801)
found in MAD04.
The infectivity of the viral RNAs synthesized in vitro from the
parental and chimeric cDNAs were tested in transfection
experiments using HEp-2c cells. Infectivity ranged from 7.5 10
3
to 4.9 10
4 pfu/mg of transfected viral RNA, with recombinant
cCA17/S2 RNA showing the lowest infectivity rate. These results
Figure 1. Phylogenetic tree depicting genetic relationships
between nucleotide sequences of CA17.67591, cVDPVs and
other HEV-C prototypes. This neighbor-joining tree was based on
nucleotide sequences alignment of genomic regions P1, which encode
viral capsid proteins. Branch lengths were calculated using PUZZLE and
the Hasegawa, Kishino and Yano (HKY) model of substitution. The
genetic distance is indicated (bar). Numbers at nodes correspond to the
percentage of 10,000 puzzle steps supporting the distal cluster.
Nucleotide sequences of enterovirus 70 (EV70) were used as an
outgroup.
doi:10.1371/journal.ppat.1000412.g001
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viable viruses in HEp-2c cells, and that essential functions of the
chimeric cDNAs were not impaired in comparison to their cDNA-
derived parental viruses.
Phenotypic characteristics of chimeric viruses
Replication kinetic assays. Replication kinetics of the
chimeric cDNA-derived viruses were compared to those of the
parental viruses in single-step growth curves (HEp-2c, 37uC). The
Figure 2. Comparative analysis of the genomic sequences of CA17.67591, cVDPVs and HEV-C prototype strains. A) Similarity between
the genomic sequences of CA17.67591 and other strains: prototype strains CA17-G12 and CA13-Flores, Madagascar cVDPVs MAD04 and MAD29,
vaccine strain Sabin 2. The genetic organization of the PV genome is shown. B) Bootscanning plot of MAD04, MAD29, Sabin 2 and CA17 sequences
versus CA17.67591 sequences (query sequence). Similarity and bootscanning analysis were performed with a sliding window of 400 nt, with a step of
20 nt (Simplot software version 3.5.1).
doi:10.1371/journal.ppat.1000412.g002
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natural CA17.67591 isolate. The final viral yield was slightly lower
for the cCA17/S2 virus than for cCA17 (Fig. 4A). However, the
growth curves for cS2/CA17, cMAD04(2A)/CA17 and
cMAD04(2A)/S2 were similar to those for viruses cS2 and
cMAD04 (Fig. 4A and 4B). In HEp-2c cells, viruses bearing the 59
half of the genomic sequence from CA17.67591 (cCA17 and
cCA17/S2) had a lower capacity to replicate than viruses
harboring 59 sequence derived from Sabin 2 (cS2 or cMAD04).
The 39 half of either cS2 or cMAD04 could be replaced by that of
cCA17 (in cS2/CA17 and cMAD04(2A)/CA17) without affecting
viral replication.
Viral plaque assay. We investigated the capacity of chimeric
and parental viruses to spread and form plaques in HEp-2c cell
monolayers in a semi-solid medium (Fig. 5). Whereas CA17.65951
isolate and its cDNA-derived counterpart cCA17 formed very
small plaques, cMAD04 formed very large plaques (Fig. 5A). The
original Sabin 2 strain virus and cS2 formed plaques of an
intermediate size. The chimeric cCA17/S2 formed very small
plaques similar to those of cCA17, suggesting that the 59 half of the
cCA17 sequence determines the very small plaque size phenotype.
Plaques formed by cS2/CA17 and cMAD04(2A)/S2 were of an
intermediate size, between those formed by cS2 and cMAD04.
cMAD04(2A)/CA17 produced plaques with a similar size to, or
even slightly larger than those of cMAD04 (Fig. 5B). Taken
together, these findings demonstrated that the 39 half of the cCA17
genome modulates viral plaque size phenotype. In particular, the
recombinant cS2/CA17 formed larger plaques than its parents
cS2 and cA17.
Temperature sensitivity. As the original PV vaccine strains
are temperature sensitive, we compared the replication kinetics of
parental and chimeric strains in single-step growth curve
experiments in HEp-2c cells at a supra-optimal temperature
(40.2uC) (Fig. 4C). The capacity of viruses cCA17 and cCA17/S2
to replicate was lower at this temperature than at 37.0uC. Eight
hours post-infection (plateau), titers were 1.3 to 2 log10 TCID50/
ml (tissue-culture infectious dose 50 per ml) lower than at 37.0uC.
Significant viral inactivation could be observed between 8 and
24 hours post-infection. Multiplication of cCA17/S2 was slightly
slower than that of cCA17. cS2 also had lower titers at 40.2uC
than at 37.0uC (plateau values reduced by 2 log10 TCID50/ml)
and showed some inactivation between 8 and 24 hours post-
infection. cS2/CA17 replicated more efficiently than cS2 and did
not show a drop in titer after 8 hours post-infection. The cS2/
CA17 growth curve showed some similarity to that of
cMAD04(2A)/S2. The highest final yields were obtained with
cMAD04 and cMAD04(2A)/CA17, which were fairly resistant to
high temperature, with levels about 0.5 log10 TCID50/ml lower at
40.2uC than at 37.0uC, 24 hours post-infection.
The temperature sensitivity of viruses was also evaluated by
titrating the same viral stock at 37uC and 40.2uC (Table 2). The
original Sabin 2 (S2) strain, the CA17.67591 isolate and their
cDNA-derived counterparts cS2, cCA17 and the recombinant
cCA17/S2 were highly temperature sensitive; indeed, the titer was
reduced by $3.6 log10 TCID50/ml at 40.2uC. The differences in
titer for cMAD04, cMAD04(2A)/CA17 and the non-temperature
sensitive environmental Sabin 2-derived S2 4568 isolate were
#0.55 log10 TCID50/ml. cS2/CA17 and cMAD04(2A)/S2
exhibited intermediate differences in titer, of about 1.2 and 1.4
log10 TCID50/ml, respectively.
These results showed that the 39 half of the cCA17 genome
renders the chimeric cS2/CA17 less temperature sensitive than
the cS2, and makes the cMAD04(2A)/CA17 not temperature
sensitive, like MAD04. Potential mutations in the cS2/CA17 viral
stock were checked by sequencing at nt positions 481 (59UTR) and
VP1 codon 143. These positions are unstable in vaccinated
individuals and are implicated in temperature sensitivity and
attenuation [27,44–47]; no unexpected mutations were found.
Neurovirulence of chimeric viruses
The pathogenicity of chimeric and parental viruses was
evaluated in homozygous PVR-Tg21 mice that express the gene
encoding the human poliovirus cellular receptor [48,49]. Follow-
Table 1. Sequences comparative analysis: CA17.67591 versus
CA17-G12, Sabin 2, MAD04 and MAD29 strains.
Genomic region
59UTR P1
a P2
b 2A 2B 2C P3
c 39UTR
CA17-
G12
Amino acid (%) n.a.
d 94 95 91 90 98 98 n.a.
Nucleotide (%) 88 78 80 78 78 81 85 100
Sabin 2 Amino acid (%) n.a. 78 96 95 94 97 97 n.a.
Nucleotide (%) 81 70 80 80 81 80 84 96
MAD04 Amino acid (%) n.a. 78 98 93 99 100 99 n.a.
Nucleotide (%) 81 70 89 79 93 93 87 99
MAD29 Amino acid (%) n.a. 78 98 95 97 99 99 n.a.
Nucleotide (%) 81 70 86 80 86 89 88 100
aP1: genomic region encoding capsid proteins VP1 to VP4.
bP2: genomic region encoding proteins 2A to 2C.
cP3: genomic region encoding the proteins 3A to 3D
pol.
dn.a.: not applicable.
doi:10.1371/journal.ppat.1000412.t001
Figure 3. Genomic structure of parental and chimeric viruses
generated in vitro. The genetic organization of the PV genome is
shown (at the top). Closed triangles indicate natural or in vitro
recombination sites.
doi:10.1371/journal.ppat.1000412.g003
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and intranasal (mucosal) routes, these animals developped
symptoms similar to those observed in humans (paresis, acute
flaccid paralysis or death). In this study, viruses were inoculated
intracerebrally (IC) and intranasally (IN).
Viruses with the 59 half genome from the original CA17 or S2
viruses — i.e. CA17.67591, cCA17, cCA17/S2, cS2, and cS2/
CA17 — did not induce paralysis or death in mice at the highest
doses inoculated IC (Table 2) or IN. Thus, they were weakly or not
pathogenic in adult PVR-Tg21 mice. All other viruses with the 59
half genome from the VDPVs MAD04, cMAD04, cMAD04(2A)/
S2, cMAD04(2A)/CA17, and the highly neurovirulent environ-
mental isolate S2 4568 [50] were pathogenic following IC or IN
inoculation.
To determine the dose that induces paralysis or death in 50% of
mice (PD50), PVR-Tg21 mice were inoculated IC with serial
dilutions of viral stocks (Table 2). The PD50 of cMAD04 and
cMAD04(2A)/CA17 were similar (3.5 and 3.8 log10 TCID50) but
lower than that of cMAD04(2A)/S2 (5.0 log10 TCID50). S2 4568
was the most pathogenic (PD50: 2.7 log10 TCID50).
A given dose of virus was also inoculated IN in PVR-Tg21 mice
(Fig. 6). Mice inoculated with cMAD04(2A)/S2 were significantly
less affected than those receiving cMAD04, cMAD04(2A)/CA17
and S2 4568 (Log Rank test: p,0.02). Pathogenicity of
cMAD04(2A)/CA17 did not differ significantly from that of
cMAD04 and S2 4568 (p.0.4).
These data confirmed that MAD04 neurovirulence is primarily
associated with the 59 half of the genome of mutated Sabin 2 and
that the 39 half of the MAD04 genome modulates the degree of
pathogenicity. These results also showed that the 39 half of the
genome from CA17.67591 can replace that from MAD04,
rendering the recombinant cMAD04(2A)/CA17 almost as neuro-
virulent as MAD04.
Discussion
Most cVDPVs reported so far were recombinants with
unidentified non-poliovaccine enteroviruses — either wild PVs
or non-PV HEV-C [3,6–13]. Many of these cVDPVs were
isolated in countries where wild polioviruses had disappeared,
suggesting that these sequences were acquired by genetic
recombination with non-PV HEV-C [5]. The co-circulation of
such recombinant cVDPVs with genetically related HEV-C
Coxsackie A viruses was recently reported in Cambodia and
Madagascar [12,27]. Our studies showed for the first time that
non-vaccine sequences present in a recombinant cVDPV can be
replaced by homologous sequences of a co-circulating Coxsackie A
virus. This provides further evidence that natural recombination
occurs between OPV strains and non-PV HEV-C.
The characterization of the in vitro engineered MAD04(2A)/
CA17 recombinant demonstrated that most of the P2 and P3
regions and the 39UTR of the cVDPV MAD04 can be exchanged
with those of CA17.67591 without significantly affecting pheno-
typic characteristics, such as viral multiplication in infected cells or
pathogenicity in PVR-Tg mice. Additionally, changes in viral
phenotype were observed when the 39 half of the CA17.67591
genome was introduced into the vaccine Sabin 2 cDNA-derived
Figure 4. Single-step growth curves of parental and chimeric
viruses. HEp-2c cells were infected with the indicated viruses, at a
multiplicity of infection of 25 TCID50 per cell, and were incubated at
37.0uC (curves A and B) or 40.2uC (curves C). Viruses were harvested at
various time points, and titrated. Standard errors of the mean of
different samples are represented as error bars.
doi:10.1371/journal.ppat.1000412.g004
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plaques in semi-solid medium and was much less temperature
sensitive than cS2. Primary recombination events can therefore
modify the phenotype of recombinants. Provided that the same
differences hold true in the human gut, such a Sabin 2/CA17
recombinant could have advantages over Sabin 2 in nature, in
terms of multiplication in the infected host, inter-human
transmission or both. The viral population may be initially
enriched for the newly formed recombinants.
Nevertheless, the cS2/CA17 recombinant was not neuroviru-
lent in PVR-Tg21 mice. This confirmed that the mutated Sabin 2-
derived 59 half of the MAD04 genome, and in particular certain
mutations in the 59UTR ribosomal entry-site (nt 481) and in the
VP1 genomic region (codon 143), are essential for pathogenicity
[46,47]. However, the fact that the recombinant MAD04/CA17
was more neurovirulent than MAD04/Sabin 2 suggests that the 39
half of the CA17.67591 genome acts to promote neurovirulence.
Alternatively, the 39 half of the Sabin 2 genome, could interact
with MAD04 to reduce neurovirulence. In any case, recombina-
tion between a slightly pathogenic vaccine PV mutant and a HEV-
C strain may make the recombinant more pathogenic. In addition,
recombination between an original vaccine PV and a HEV-C
strain may favor viral multiplication, circulation and therefore
genetic drift and acquisition of pathogenic characteristics.
Regardless of the sequence of events leading to formation of
pathogenic recombinants — whether mutations occur first then
subsequent recombination or vice versa — recombination between
vaccine PV and HEV-C may favor the emergence of cVDPVs.
The contribution of the 39 half of the CA17 genome to
phenotypic differences observed between PV/CA17 recombinants
and PV strains remains unclear. Previous studies have shown that
the P3-39UTR region of PV, Coxsackievirus B3 and enterovirus
71 strains is implicated in pathogenicity in animal models and/or
in temperature sensitivity of viruses [51–54]. It may also modulate
diversity among quasispecies by affecting polymerase fidelity, as
recently shown for type 1 PV [55]. Recombination between PV
and CA17 brings together different genomic fragments. Interac-
tions between these genomic regions may then account for the
specific features observed in these recombinants. The intrinsic
properties of the 39 half of CA17 genome and the encoded
proteins, and their functional interactions with their PV counter-
parts, remain to be determined. This will help to elucidate the
mechanisms by which recombination modifies the phenotype and
gives rise to the emergence of recombinant cVDPVs.
The prototype HEV-C strains CA11, CA13, CA17 and CA20
are the most closely genetically related to PV [14,15]. Viral isolates
belonging to these four serotypes (characterized from VP1
nucleotide sequences) were found in Madagascar in the district
of Tolagnaro where the four polio cases caused by MAD04 lineage
cVDPVs were identified [11,27]. The sequencing of the whole
genome of one of the CA17 isolates (CA17.67591) which has a
high sequence similarity to MAD04 in the 2C region, confirmed its
genetic link with the MAD04 lineage and revealed that it is also
related to the MAD29 lineage found in another district. We also
identified genetic links between this CA17 isolate and the different
recombinant cVDPVs lineages isolated in 2005 from other
Madagascar districts [10] (Joffret et al. unpublished). CA17 strains,
or at least viruses related to the CA17.67591 lineage, thus appear
to belong to the common recombinant partners of PV in
Madagascar. One study showed that the 2BC genomic region of
a Sabin3/HEV-C recombinant from Cambodia was related to the
Figure 5. Plaque size of chimeric and parental viruses. Plaque assays were performed on HEp-2c cell monolayers infected with serially diluted
viral stocks and incubated at 37uC for 72 h with semi-solid medium. Relative diameters were calculated, taking the average value of cMAD04 plaque
diameters to be 100%. Relative plaque sizes (with standard deviations) of two experiments are indicated for viruses in series A and series B. The
original Sabin 2 strain (S2) and the corresponding cDNA-derived virus (cS2) were used in series A.
doi:10.1371/journal.ppat.1000412.g005
Table 2. Temperature sensitivity and pathogenicity of
parental and chimeric viruses following IC inoculation.
Virus strain
Temperature sensitivity
Dlog10TCID50/ml
(37.0uC–40.2uC)
a
PD50 log10TCID50/
mouse
b
S2 3.8560.05 n.d.
c
CA17.67591 3.660.1 .5.6
d
cS2 3.8560.05 .7.6
d
cCA17 3.8560.15 .5.6
d
cCA17/S2 4.5560.05 .5.6
d
cS2/CA17 1.260.1 .7.6
d
cMAD04 0.3560.15 3.860.4
cMAD04(2A)/CA17 0.4560.05 3.560.4
cMAD04(2A)/S2 1.460.1 5.060.3
S2 4568 0.5560.15 2.760.3
aThe data are arithmetic means from two experiments; standard errors from the
mean are indicated.
bThe paralytic doses affecting 50% of mice following inoculation (PD50)a n d
standard errors are indicated.
cn.d.: not determined.
dNo paralysis occurred following inoculation of the highest doses indicated.
doi:10.1371/journal.ppat.1000412.t002
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recombination rate that occurs naturally in all human enterovirus
species [4,14,20,25,26,28,57], we cannot exclude the possibility
that other HEV-C strains or HEV-C/CA17 recombinants are
actually the parents of the Madagascar cVDPVs. However, no
such recombinants have been detected among the various HEV-C
isolates having been collected in the Tolagnaro district [27]. CA13
isolates from Tolagnaro were also found to be genetically related
to MAD04 and MAD29. Recombination of PV with CA13 strains
or with CA17/CA13 recombinant strains may be important for
certain viral functions and for the emergence of cVDPVs.
However, all the phenotypic characteristics of MAD04/CA17
were similar to those of MAD04. This suggests that sequences in
the 3D
pol region of the cVDPV MAD04, which are related to
those of certain co-circulating CA13 strains, do not confer
additional selective advantages, at least in terms of the viral
functions and characteristics studied.
Whether CA11, CA20 or some other HEV-C are involved in
recombination with PV in humans remains unclear. The 2C
sequences of a CA20 isolate from Tolagnaro were previously
found to be related to those of MAD04 [27]. A recent study of
recombinants between the highly pathogenic PV strain Mahoney
and a prototype HEV-C (CA20) suggested that the P2 or the P3
regions of the poliovirus genome can be exchanged with those of
CA20 without any effect on viral multiplication and, in at least
some cases, on pathogenicity in PVR-Tg mice [58]. However, this
study demonstrated that recombinants containing the capsid of
CA20 (or CA21) and PV sequences are either dysfunctional or
non-viable. Combinations of sequences and/or functions derived
from PV and other HEV-C may therefore not be compatible and
may limit recombinants variety. In this study, the chimera cCA17/
S2 (with the 59UTR and the capsid of CA17.67591) was viable,
with multiplication and temperature sensitivity differing only
slightly from cCA17. The CA20 - PV Mahoney pair appears to be
less permissive for reciprocal genetic exchange than the CA17 –
Sabin 2 pair. Unlike a CA20/type 1 PV Mahoney recombinant
(with the CA20 capsid), the CA20/type 3 PV Leon counterpart
was viable [58], suggesting that some viral factors (phylogenetic
distance between viruses and/or functional determinants) may
determine the viability and functional properties of recombinants.
Nevertheless, small defects in viral function such as those found in
CA17/S2 (compared to CA17) may result in selective disadvan-
tages in humans. To the best of our knowledge, CA17/PV
recombinants have not yet been isolated from humans.
In conclusion, this study shows that a CA17 isolate co-
circulating with a PV/HEV-C recombinant cVDPV can be a
recombination partner for PV. Recombination can have a
beneficial primary effect on the key phenotypic characteristics of
recombinants such as replication and may thus favor the
emergence of pathogenic cVDPVs. PVs and CA17 have been
recently classified as belonging to the same enterovirus species due
to the similarity of their nucleotide sequences; however, these
viruses differ greatly in terms of biological properties and
pathogenicity in humans. PVs recognize CD155 as its viral
receptor [59] and induce a severe paralytic disease. The binding of
CA17 to cells seems to be mediated by ICAM1, similarly to the
major group of rhinoviruses, agents of the common cold [60].
Moreover, CA17 strains are thought to be poorly pathogenic or
not pathogenic at all in humans [61]. The co-circulation of these
very different viruses in populations of children [27], and their
evolution through intertypic genetic recombination may result in
the appearance of more efficiently replicating variants enabling the
emergence of new pathogenic lineages. This constitutes an
interesting model of viral evolution and emergence.
Materials and Methods
Cells and Viruses
HEp-2c cells (derived from a human laryngeal carcinoma cell
line) were grown as monolayers in DMEM(16) high Glucose (with
tricine, biotin) (PAA) supplemented with 1% of L-Glutamine
200 mM and 10% new born calf serum.
Figure 6. Neurovirulence of viruses inoculated intranasally (IN) in transgenic PVR-Tg mice. A given viral dose (10
6 TCID50 for
neurovirulent viruses) was used to inoculate groups of PVR-Tg mice expressing the human poliovirus receptor (9 mice per virus). Animals were
checked daily for paralysis and death, for 21 days post-inoculation. Healthy mice ratios following inoculation of parental or chimeric viruses or
neurovirulent positive-control virus S2 4568 are shown. No symptoms were observed following the inoculation of the highest doses of cCA17 and
cCA17/S2 (10
5 TCID50 per mouse) or cS2 and cS2/CA17 (10
7 TCID50 per mouse) – not shown for the last three viruses.
doi:10.1371/journal.ppat.1000412.g006
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sequences HEp-2c cell monolayers were grown in DMEM
medium containing tryptose phosphate broth and tricine
(DMEM-TPB), supplemented with 1% of L-Glutamine
200 mM, 2% of sodium bicarbonate 7.5% and 3% fetal calf
serum (FCS).
The coxsackie A virus CA17.67591 strain was isolated in 2002
and grown in HEp-2c cells from stools of healthy child living in the
district of Tolagnaro, Madagascar [27].
The cVDPV strain MAD04 was isolated from stool specimens
of a patient with poliomyelitis during the 2002 outbreak in
Tolagnaro district [11,27]. The corresponding cDNA-derived
virus cMAD04 used in this study was previously described [31].
The poliovaccine virus Sabin 2 (S2) was obtained from the
WHO [Behringwerke (S0+1)] ‘‘master seeds’’. A second passage at
36uC in HEp-2c cells of the original seed was used to prepare viral
stocks. The corresponding cDNA-derived cS2 was also used [31].
The PV strain S2/4568 is a non-temperature sensitive and
highly neurovirulent Sabin 2 -derived strain isolated from sewage
in Israel [50].
The CA17 prototype strain G12 (CA17-G12) was kindly
supplied by the National Institute of Public Health and the
Environment (RIVM), Bilthoven, The Netherlands and amplified
on HEp-2c cells.
RT-PCR and sequencing
Oligonucleotides used for RT-PCR are presented in Table 3;
most polioviruses- and enterovirus-specific primers were previously
described [22,33,62,63]. Viral RNA was extracted with QIAampH
Viral RNA Mini Kit (QIAGEN), according to the manufacturer’s
instructions. Reverse transcription was realised as described by
Bessaud et al. [64], using the P1c primer. PCR was carried out in a
final volume of 50 ml including 5 ml of Taq Buffer 106 with
MgCl2, 200 mM of each dNTPs, 10 pmoles of each primers, 5 ml
of cDNA and 2.5 U of Taq DNA polymerase (Taq CORE kit 10,
Q-Biogen). The thermocycler profile was that of 20 sec at 94uC,
followed by 40 cycles of 30 sec at 94uC, 30 sec at 45uC, 1 min at
72uC, and a final elongation step of 10 min at 72uC. PCR
products were analysed on ethidium bromide stained agarose gels
and purified with QIAquick PCR Purification kit (QIAGEN). The
sequences of the resulting amplicons were determined using the
BigDye terminator v3.1 kit (Applied Biosystems) and an ABI Prism
3140 automated sequencer (Applied Biosystems) using in most
cases primers used for the PCR reaction.
The 59-end of the viral genome was amplified with the 59/39
RACEkit (Roche), as described in the manufacturer’s protocol.
Briefly, viral RNA was used for first-strand cDNA synthesis using
the primer UC52; the cDNA was purified and a dA-tailing
reaction was carried out. The dA-tailed cDNA was then amplified
by PCR using the UC52 and oligo-dT primers.
Alignment of sequences and genetic analysis
Sequences were aligned and compared using CLC Combined
Workbench 3.0 software (CLC bio, Aarhus, Denmark).
Phylogenetic relationships between sequences were inferred by
the maximum likelihood method with PUZZLE 4.0, which uses
QUARTET PUZZLING as the tree search algorithm [65]. The
Hasegawa, Kishino and Yano (HKY) model of substitution for nt
with a Ts/Tv of 8.0 was used [66]. Trees were constructed using
neighbor-joining of PHYLIP (Phylogeny Inference Package)
version 3.6 [67] and branch length given by PUZZLE. The
reliability of tree topology was estimated using 10,000 puzzle steps.
Trees were drawn with NJ Plot [68].
Table 3. Oligonucleotides used for RT and PCR.
Genomic
region Name
a Sequences 59-.39
b
Poliovirus-specific primers
59UTR UG52 (162) CAAGCACTTCTGTTTCCCCGG (182)
UC52 (182) CCGGGGAAACAGAAGTGCTTG (162)
UG53 (578) TGGCTGCTTATGGTGACAAT (597)
UC53 (596) TTGTCACCATAAGCAGCCA (578)
VP2 UG21 (1177) TCGAGAGGGTGGTGGTGGAA (1196)
UC21 (1205) TCAGGTAATTTCCACCACCA (1186)
VP3 UC20 (2423) TCATTACACGCTGACACAAA (2404)
UG1 (2404) TTTGTGTCAGCGTGTAATGA (2423)
2A UC11 (3503) AAGAGGTCTCTATTCCACAT (3484)
UG13 (3616) CCCACCTTCCAGTACATGGA (3635)
2C UG23 (4168) AAGGGATTGGAGTGGGTGTC (4187)
UC22 (4151) TCAGTAAATTTCTTCAAC CA (4132)
UG15 (4935) CTGTCACCAACCAGCAAACTT (4955)
UC15 (4964) CATCTCTTGAAGTTTGCTGG (4945)
3C UG16 (5920) GTTGGTGGGAACGGTTCACA (5939)
UC16 (5939) TGTGAACCGTTCCCACCAAC (5920)
3D UC8 (6375) GATGTCTCTCTTCTTCTTTCCC (6354)
UG7 (6085) TTTGAAGGGGTGAAGGAACCAGC (6107)
UG31 (6913) CTGAAAACCTACAAGGGCATAG (6934)
Enterovirus-specific primers
VP1 EUG3a+b (3004) TGGCAAACT/ATCC/TW/TCC/MAAC/TCC
(3023)
2C EUC2 (4453) TTTGCACTTGAACTGTATGTA (4473)
EUG19 (4747) AAGGGCATTTTGTTCACGTC (4766)
3A EUC18 (5237) ATCCATCCTTTCTTCTCACA (5218)
3D EUG12a+b (6952) ATGATTGCCTATGGC/GGAT/YGAT/CGT (6974)
EUC12a (6974) ACATCGTCMCCATATGCRATCA (6952)
39UTR P1c AGCTGATCGATGGGCTACCATGCGTACCC(T)21C
CA17-specific primers
VP2 CAG1051 (1051) GTTGCCTATGGTCGCTGGCC (1070)
CAC1422 (1422) CACACCCCCACTTTCACCTGG (1402)
VP3 CAG2285 (2285) GCAACACAGCATACCGGCG (2303)
VP1 CAC2959 (2959) CTTGGTTTCTTGCATGCCCG (2940)
2A CAG3499 (3499) GTCATGTGGAATAGAGACC (3517)
2B CAC3891 (3891) CCCAAATGCAGCTCCAAGGG (3872)
3C CAG5721 (5721) CATCCCCACTCAAATCACCG (5740)
3D CAC6142 (6142) CGTTCCTGGTCAACACAGCC (6123)
CAG6837 (6837) GACATACTGTGTCAAGGGCG (6856)
CAC7040 (7040) GATTGGGCTAGGAGACTAGC (7021)
Other
2C Mc4171 (4171) CCTTAGCAGCATTACATGC (4153)
59UTR OdT GACCACGCGTATCGATGTCGAC(T)16A
aMost polioviruses- and enterovirus-specific primers have been previously
described (see Materials and Methods for references).
bNumbers in brackets refer to the nucleotide positions of Sabin 2 genomic
sequences.
except for CA17 specific primers whose numbers refer to CA17.67591 genomic
sequences.
doi:10.1371/journal.ppat.1000412.t003
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analysis were PV sequences of PV1-Mahoney, PV2-Lansing, PV3-
Leon, Sabin1, Sabin2, Sabin3, MAD04, MAD07, MAD29
(GenBank accession numbers: V01149, M12197, K01392,
AY184219, AY184220, AY184221, AM084223, AM084224,
AM084225, respectively), nt sequences of prototype strains CA1-
Tompkins, CA11-Belgium1, CA13-Flores, CA11v-G9, CA17-
G12, CA13v-G13, CA19-NIH8663, CA20-IH35, CA21-Kuyken-
dall, CA21(V)-Coe, CA22-Chulman, CA24v-EH24/70 (Genbank
numbers: AF499635, AF499636, AF499637, AF499638,
AF499639, AF499640, AF499641, AF499642, AF546702,
D00538, AF499643, and D90457, respectively) and, finally, nt
sequence of the prototype strain EV70-J670_71 belonging to the
human enterovirus of species D (GenBank number: D00820),
which was used as outgroup sequence. Former CA15 and CA18
are considered as antigenic variants of CA11 and CA13 [16], and
are now named CA11v and CA13v, respectively
Similarity scanning (similarity plots) and bootscanning analysis
[43], which depicted relationships among the aligned sequences,
were generated using the Simplot software version 3.5.1 [42].
Similarity and bootscanning analysis were performed with a
sliding window of 400 nt and a step of 20 nt using Kimura 2
parameters and a transition/transversion ratio of 10. Bootscanning
was performed using the neighbour-joining method. Bootscanning
consists in the alignment of a possible recombinant sequence with
putative parental reference sequences. Bootstrapped phylogenetic
trees are built for each segment and finally the bootstrap value for
placing the suspected recombinant sequence with the group of a
putative parental sequence (CA17.67591 in this study) is plotted
along the genome.
Prediction of viral RNA secondary structure was performed
using a modified version of MFOLD available in CLC Combined
Workbench software [69].
Construction of parental and chimeric cDNA-derived
viruses
The molecular cloning of the Sabin 2 cDNA and the MAD04
cDNA in a modified pBR322 vector (pBR-S2 and pBR-MAD04,
respectively) has been previously described [31].
Viral RNA isolated from the CA17.67591 viral stock was
reverse transcribed and the cDNA was amplified using PCR as
described above except that the Pfu Ultra II Fusion HS DNA
polymerase (STRATAGENE) was used.
Two chimeric Sabin 2/CA17.67591 genomes (cS2/CA17 and
cCA17/S2) were constructed. Plasmids, oligonucleotides and
restriction sites used are given in Table 4. To get the cS2/CA17
cDNA (recombination site at nt 3827), a PCR fragment correspond-
ing to the 39 half of the CA17 cDNA was amplified with specific
primers containing BseRI and NotI cloning restriction sites (Fig. 3)
and used to replace the homologous fragment in pBR-S2. To
construct cCA17/S2 cDNA, an AscI-BseRI restriction fragment
amplified from CA17.67591 by RT-PCR was used to replace the
homologous 59 half of the Sabin 2 cDNA present in pBR-S2. The
parental complete CA17 cDNA was reconstituted by replacing the
Sabin 2 part of cCA17/S2 cDNA, by the 39 half of the CA17 cDNA
(BseRI-NotI fragment) present inthe cloned cS2/CA17 cDNA. This
CA17 fragment was also used to replace the Sabin 2 part of the
previously described MAD04(2A)/S2 cDNA [31] to give the
MAD04(2A)/CA17 cDNA.
All constructs were verified by sequencing and CA17 cDNA
sequences were compared to the original CA17.67591 viral stock.
The original isolate differs from the cDNA by a few nucleotides
(nucleotides 68 G-.T, 89 A-.T, 2053 U-.C, 2401 U-.C, 2730
C-.T, 2794 G+A-.A: Thr+Ala-.Thr, 2997 G-.A, 3819 U-
.G, 3825 A-.T, 3834 A-.G, 3840 C-.T, 4302 A-.G, 4809 C-
.T, 6906 C-.T, 7339 C-.T, respectively).
The T7 RNA
pol promoter localised upstream the cloned viral
cDNA was used to transcribe infectious RNAs from linearized
plasmid (T7 RiboMAX
TM,P R O M E G A ) .D N Am a t r i x e sw e r e
eliminated by treatment with RQ1 RNase-Free DNase and viral
RNA was purified by phenol/chloroform extraction or with the
RNeasy mini kit (QIAGEN). HEp-2c cell monolayers were
transfected with purified RNAs (Lipofectamine 2000, INVI-
TROGEN) and incubated at 37uC, 5% CO2. Viral stocks were
obtained following transfection of 9 mgo fR N A / 1 0
6 cells in
DMEM-TPB supplemented with 3% FCS. After almost
complete cytopathic effect, viruses were harvested and viral
stocks were constituted following two subsequent passages in
HEp-2c cells.
Table 4. Initial plasmids, oligonucleotides, and restriction sites used for constructing viral infectious cDNAs.
Plasmidic
Infectious cDNA Initial plasmids
a Oligonucleotides used for amplifying CA17.67591 sequences
b Cloning sites
pBR-S2/CA17
(11123 bp)
pBR-S2 (11123 bp) Sense (3825)59GGAGCAAGGCATTTCCAATTACATCGAG39(3852) BseRI (3827)
NotI (7457)
Antisense (7473)59AAGGAAAAAAGCGGCCGCTTTTTTTTTTTTTTTTCTCCGAATTAAAGAAAAATTTA-39(7418)
pBR-CA17/S2
(11141 bp)
pBR-S2 (11123 bp) Sense (11092)59TCGCCGGCGCGCCTAATACGACTCACTATAGGTTAAAACAGCTCTGGGGTTG39(20) AscI (11098)
BseRI (3827)
Antisense (3842)59TTGGAAATGCCCTGCTCCATAGCTTCCTCCTCATAAGCATACAGGTCTCTAATGTC39(3787)
pBR-CA17
(11141 bp)
pBR-CA17/S2
(11141 bp)
Sense (3843)59GGAGCAAGGCATTTCCAATTACATCGAG39(3870) BseRI (3844)
NotI (7475)
Antisense (7491)59AAGGAAAAAAGCGGCCGCTTTTTTTTTTTTTTTTCTCCGAATTAAAGAAAAATTTA-39(7436)
pBR-MAD04(2A)/
CA17 (11141 bp)
pBR-MAD04(2A)/S2
(11123 bp)
Sense (3825)59GGAGCAAGGCATTTCCAATTACATCGAG39(3852) BseRI (3827)
NotI (7457)
Antisense (7473)59AAGGAAAAAAGCGGCCGCTTTTTTTTTTTTTTTTCTCCGAATTAAAGAAAAATTTA-39(7418)
aAll initial plasmids except pBR-CA17/S2 have been previously described by Riquet et al. [51].
bNumbering refers to the nucleotide sequences of the viral cDNA in the initial plasmid. The nucleotide sequence of the restriction sites used for constructing plasmid
are underlined.
doi:10.1371/journal.ppat.1000412.t004
Poliovirus-Coxsackievirus Recombinants
PLoS Pathogens | www.plospathogens.org 10 May 2009 | Volume 5 | Issue 5 | e1000412RNA Infectivity assay
The infectivity of the cDNA-derived viral RNAs was tested by
transfecting different amounts of viral RNAs in HEp-2c cell
monolayers that were subsequently maintained under a 1.2%
Avicel (FMC Biopolymer) overlay [70]. Six-well plastic plates were
seeded with 2610
6 HEp-2c cells per well in DMEM-TPB
supplemented with 1% of L-Glutamine 200 mM, 2% of sodium
bicarbonate 7.5% and 3% FCS and kept in an incubator at 37uC
and 5% CO2 for about 24 h. Cell monolayers were washed twice
with DMEM without serum, transfected using Lipofectamine 2000
with 1 mg of decimally diluted RNA per well and incubated at
37uC and 5% CO2 for 30 min. Then, the inoculum was removed
and replaced by 2 ml per well of DMEM-TPB supplemented with
1% of L-Glutamine 200 mM, 2% of sodium bicarbonate 7.5%
without serum before incubation at 37uC and 5% CO2 for 1 h.
Next, the medium was removed and replaced by 3 ml of a mixture
containing 1 volume of 2.4% Avicel in water and 1 volume of
DMEM 26 supplemented with 2% L-glutamine 200 mM, 2%
penicillin/streptomycin 1006, 4% tricine 1 M pH 7.4, 3%
sodium bicarbonate 7.5%, 5% MgCl2 1 M and 4% FCS. Plaques
were incubated at 37uC in a 5% CO2 incubator for 3 days. Avicel-
containing medium was then removed; cells were washed twice
with PBS (without CaCl2, MgCl2) and stained. The number of
plaque forming unit (pfu) per mg of transfected RNA was
calculated (mean of two experiments).
Viral plaque assay
Six-well plastic plates seeded with HEp-2c cells were prepared as
described in the RNA infectivity assay. They were infected with
500 ml per well of decimally diluted viral stocks. Following washing,
incubation under Avicel at 37uC for 3 days and staining, the
diameter of all isolated plaques was measured and a mean plaque
diameter and standard deviation (two experiments) were calculated.
Replication kinetic assay
Replication kinetics of parental and chimeric viruses were
compared in single-step growth experiments. HEp-2c cells were
infected at a multiplicity of infection of 25 TCID50 per cell. After
adsorption for 30 min, cells were washed twice and incubated at
37.0uC in a 5% CO2 incubator or at 40.2uC in a water bath.
Then, infected cells were frozen at various time points post-
infection. Viral titers were determined for each time (TCID50/ml).
Temperature sensitivity
In addition to single-step growth at 40.2uC, the temperature
sensitivity of viruses was also evaluated by titrating the same viral
stock (TCID50/ml) at various temperatures in DMEM-TPB
containing 2.2% FCS. One plate was incubated at 37.0uC
(optimal temperature) in a 5% CO2 incubator and the second
was incubated at 40.2uC (supra-optimal temperature) in a water
bath. After 5 days of incubation, cells were stained and the titer
(TCID50/ml) was calculated for each temperature. Results are
expressed as the difference between the viral titre measured at
37.0uC and that at 40.2uC.
Assay of neurovirulence in PVR-Tg mice
Virus neurovirulence was tested in homozygous PVR-Tg21
mice that constitutively express the human poliovirus receptor
CD155 (generous gift from A. Nomoto) [48]. To determine PD50
groups of 6 six-week-old PVR-Tg21 mice (equal number of males
and females) were inoculated IC with a given amount of each virus
ranging from 10
3 to 10
7 TCID50/ml in DMEM containing 0.1%
fetal calf serum (30 ml per mouse). Mice were examined daily for
21 days post-inoculation for paralysis and/or death and the PD50
was calculated by the method of Reed and Muench [71]. Standard
errors were determined according to the formula of Pizzi [72].
To evaluate neurovirulence a given dose of virus was also
inoculated IN (265 ml per mouse) in groups of PVR-Tg21 mice (5
males and 4 females or 3 males and 3 females). Survival curves
were determined according to the Kaplan-Meir method and
compared using the Log Rank test with the XLSTAT software
version 2008.6.05 (ADDINSOFT).
Viruses S2 4568 and cS2 were used as neurovirulent and non-
pathogenic controls, respectively. To confirm the inoculated dose,
viral inocula were back-titrated following inoculation.
All experiments were conducted in full compliance with French
regulations regarding laboratory animal welfare. Protocols were
approved by the Veterinary Staff of the Central Animal Facility of
Institut Pasteur. Before IC and IN inoculation mice were
anesthetized by intraperitoneal injection of 100 ml of PBS
containing 0.25 mg of Xylazine (Rompun, BAYER) and 2.5 mg
Ketamine (Imalgene, MERIAL).
Virus blocking assay
To test whether infection of HEp-2c cells by CA17.67591 was
mediated by ICAM-1, we used a monoclonal antibody (mAb)
against this molecule (clone 8.4 A6, Sigma) [40]. A mAb against the
PV receptor CD155 (mAb. 404, kind gift of Marc Lopez, Marseille)
wasusedascontrol[41].Briefly,2-daysoldconfluentHEp-2ccellsin
96-well plates were treated either by anti-ICAM-1, or anti-CD155
mAbs, or mock-treated for 2 h at 37u before infection, as described
by Minor and coll. [73]. Eachwell containing about 40,000 cells was
then infected by 10
3 TCID50 of either CA17.67591, or Sabin 2
cDNA-derived strains, or mock-infected, in the presence of
antibodies as described [73]. Cell protection was evaluated under
the microscope 4 days post-inoculation.
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